Cerevel Therapeutics Holdings (STU:673) EV-to-EBIT : -16.12 (As of May. 13, 2024)

View and export this data going back to 2022. Start your Free Trial

What is Cerevel Therapeutics Holdings EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Cerevel Therapeutics Holdings's Enterprise Value is €6,687.20 Mil. Cerevel Therapeutics Holdings's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was €-414.88 Mil. Therefore, Cerevel Therapeutics Holdings's EV-to-EBIT for today is -16.12.

The historical rank and industry rank for Cerevel Therapeutics Holdings's EV-to-EBIT or its related term are showing as below:

STU:673' s EV-to-EBIT Range Over the Past 10 Years
Min: -18.86 Med: 0 Max: 0
Current: -16.04

STU:673's EV-to-EBIT is ranked worse than
100% of 436 companies
in the Biotechnology industry
Industry Median: 9.28 vs STU:673: -16.04

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Cerevel Therapeutics Holdings's Enterprise Value for the quarter that ended in Mar. 2024 was €6,653.92 Mil. Cerevel Therapeutics Holdings's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was €-414.88 Mil. Cerevel Therapeutics Holdings's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -6.24%.

Cerevel Therapeutics Holdings EV-to-EBIT Historical Data

The historical data trend for Cerevel Therapeutics Holdings's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cerevel Therapeutics Holdings EV-to-EBIT Chart

Cerevel Therapeutics Holdings Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-EBIT

-11.78

-18.91

-12.70

-16.76

Cerevel Therapeutics Holdings Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EV-to-EBIT	Get a 7-Day Free Trial													-8.84	-11.98	-8.20	-16.76	-16.05

Competitive Comparison of Cerevel Therapeutics Holdings's EV-to-EBIT

For the Biotechnology subindustry, Cerevel Therapeutics Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cerevel Therapeutics Holdings's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cerevel Therapeutics Holdings's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Cerevel Therapeutics Holdings's EV-to-EBIT falls into.

Cerevel Therapeutics Holdings EV-to-EBIT Calculation

Cerevel Therapeutics Holdings's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	6687.202	/	-414.875
	=	-16.12

Cerevel Therapeutics Holdings's current Enterprise Value is €6,687.20 Mil.
Cerevel Therapeutics Holdings's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-414.88 Mil.

Cerevel Therapeutics Holdings (STU:673) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Cerevel Therapeutics Holdings's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 )	=	EBIT	/	Enterprise Value (Q: Mar. 2024 )
	=	-414.875	/	6653.918
	=	-6.24 %

Cerevel Therapeutics Holdings's Enterprise Value for the quarter that ended in Mar. 2024 was €6,653.92 Mil.
Cerevel Therapeutics Holdings's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-414.88 Mil.

Cerevel Therapeutics Holdings EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Cerevel Therapeutics Holdings's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Cerevel Therapeutics Holdings (STU:673) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cerevel Therapeutics Holdings Inc (STU:673) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

CERE:USA

Address

222 Jacobs Street, Suite 200, Cambridge, MA, USA, 02141

Website

https://www.cerevel.com

Cerevel Therapeutics Holdings Inc is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company is tackling neuroscience diseases with a differentiated approach that combines expertise in neurocircuitry with a focus on receptor selectivity. It has a diversified pipeline comprising five clinical-stage investigational therapies and several preclinical compounds with the potential to treat a range of neuroscience diseases, including schizophrenia, epilepsy, Parkinson's disease and substance use disorder. Cerevel Therapeutics is advancing its current research and development programs while exploring new modalities through internal research efforts, external collaborations or potential acquisitions.

Cerevel Therapeutics Holdings (STU:673) Headlines

No Headlines